Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
Author:
Affiliation:
1. School of Medicine Nankai University Tianjin China
2. Department of Oncology Chinese PLA General Hospital Beijing China
3. Department of Graduate Administration Chinese PLA General Hospital Beijing China
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14271
Reference34 articles.
1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2. Osimertinib effective in EGFR T790M-positive lung cancer
3. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer
4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
5. Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-08-23
2. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer;Canadian Respiratory Journal;2023-06-21
3. The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer;Frontiers in Oncology;2023-04-14
4. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study;Thoracic Cancer;2023-03-03
5. Osimertinib;Reactions Weekly;2023-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3